APOTEX CORP. for APOTEX CORP.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 11, 2008 | $130,000 | Replaced |
| 2nd Quarter - Amendment | Aug 1, 2008 | $130,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S 1145, Patent Reform Act of 2007, Section 12, Inequitable Conduct HR 1908, Patent Reform Act of 2007, Section 12, Additional Information, Inequitable Conduct as a Defense to Infringment
Foreign entity interest: Apotex Holdings, Inc., the parent company of Apotex Corp., has direct or indirect ownership interests that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Medicare/Medicaid MMM
Centers for Medicare and Medicaid Services Rule 2238-P concerning Medicaid prescription drug reimbursement HR 3700 & S 1951, Fair Medicaid Drug Pricing Act HR 3140, Saving Our Community Pharmacy Act HR 6331, S 3101, the Medicare Improvements for Patients and Providers Act of 2008, Section 203, Pharmacy Reimbursement Under Medicaid
Foreign entity interest: Apotex Holdings, Inc., the parent company of Apotex Corp., has direct or indirect ownership interests that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
S 316, the Preserve Access to Affordable Generics Act HR 1902, the Protecting Consumer Access to Generic Drugs Act HR 1038, the Access to Life Saving Medicine Act HR 5629, the Pathway for Biosimilars Act S 1695, the Biologics Price Competition and Innovation Act HR 5839, the Safeguarding America's Pharmaceuticals Act HR 3610, the Food and Drug Import Safety Act, Section 4, User Fees Regarding Drug Safety Draft Senate food and drug import safety legislation PL 110-85, the Food and Drug Amendments Act of 2007, Section 914, Citizen Petitions and petitions for stay of agency action Combating anti-generic subsitution legislation in the states
Foreign entity interest: Apotex Holdings, Inc., the parent company of Apotex Corp., has direct or indirect ownership interests that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.